{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-059551","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.523110+00:00","generated_at":"2026-05-16T01:38:45.596377+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents","bullets":["Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.","Ruling affirms December 2023 District of New Jersey verdict; Corcept will consider further judicial review.","CEO Joseph Belanoff expressed disappointment and said company will vigorously defend its rights.","Patents cover methods used in treating Cushing's syndrome; generic entry would weaken Korlym's market exclusivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-059551","json":"https://secwatch.observer/filing/0001193125-26-059551.json","markdown":"https://secwatch.observer/filing/0001193125-26-059551.md","text":"https://secwatch.observer/filing/0001193125-26-059551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526059551/0001193125-26-059551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526059551/d25779d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:38:45.596377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}